Impact of seasonal malaria chemoprevention on prevalence of malaria infection in malaria indicator surveys in Burkina Faso and Nigeria.
Child health
Epidemiology
Malaria
Public Health
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
16
11
2021
accepted:
13
04
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
24
5
2022
Statut:
ppublish
Résumé
In 2012, the WHO issued a policy recommendation for the use of seasonal malaria chemoprevention (SMC) to children 3-59 months in areas of highly seasonal malaria transmission. Clinical trials have found SMC to prevent around 75% of clinical malaria. Impact under routine programmatic conditions has been assessed during research studies but there is a need to identify sustainable methods to monitor impact using routinely collected data. Data from Demographic Health Surveys were merged with rainfall, geographical and programme data in Burkina Faso (2010, 2014, 2017) and Nigeria (2010, 2015, 2018) to assess impact of SMC. We conducted mixed-effects logistic regression to predict presence of malaria infection in children aged 6-59 months (rapid diagnostic test (RDT) and microscopy, separately). We found strong evidence that SMC administration decreases odds of malaria measured by RDT during SMC programmes, after controlling for seasonal factors, age, sex, net use and other variables (Burkina Faso OR 0.28, 95% CI 0.21 to 0.37, p<0.001; Nigeria OR 0.40, 95% CI 0.30 to 0.55, p<0.001). The odds of malaria were lower up to 2 months post-SMC in Burkina Faso (1-month post-SMC: OR 0.29, 95% CI 0.12 to 0.72, p=0.01; 2 months post-SMC: OR: 0.33, 95% CI 0.17 to 0.64, p<0.001). The odds of malaria were lower up to 1 month post-SMC in Nigeria but was not statistically significant (1-month post-SMC 0.49, 95% CI 0.23 to 1.05, p=0.07). A similar but weaker effect was seen for microscopy (Burkina Faso OR 0.38, 95% CI 0.29 to 0.52, p<0.001; Nigeria OR 0.53, 95% CI 0.38 to 0.76, p<0.001). Impact of SMC can be detected in reduced prevalence of malaria from data collected through household surveys if conducted during SMC administration or within 2 months afterwards. Such evidence could contribute to broader evaluation of impact of SMC programmes.
Sections du résumé
BACKGROUND
In 2012, the WHO issued a policy recommendation for the use of seasonal malaria chemoprevention (SMC) to children 3-59 months in areas of highly seasonal malaria transmission. Clinical trials have found SMC to prevent around 75% of clinical malaria. Impact under routine programmatic conditions has been assessed during research studies but there is a need to identify sustainable methods to monitor impact using routinely collected data.
METHODS
Data from Demographic Health Surveys were merged with rainfall, geographical and programme data in Burkina Faso (2010, 2014, 2017) and Nigeria (2010, 2015, 2018) to assess impact of SMC. We conducted mixed-effects logistic regression to predict presence of malaria infection in children aged 6-59 months (rapid diagnostic test (RDT) and microscopy, separately).
RESULTS
We found strong evidence that SMC administration decreases odds of malaria measured by RDT during SMC programmes, after controlling for seasonal factors, age, sex, net use and other variables (Burkina Faso OR 0.28, 95% CI 0.21 to 0.37, p<0.001; Nigeria OR 0.40, 95% CI 0.30 to 0.55, p<0.001). The odds of malaria were lower up to 2 months post-SMC in Burkina Faso (1-month post-SMC: OR 0.29, 95% CI 0.12 to 0.72, p=0.01; 2 months post-SMC: OR: 0.33, 95% CI 0.17 to 0.64, p<0.001). The odds of malaria were lower up to 1 month post-SMC in Nigeria but was not statistically significant (1-month post-SMC 0.49, 95% CI 0.23 to 1.05, p=0.07). A similar but weaker effect was seen for microscopy (Burkina Faso OR 0.38, 95% CI 0.29 to 0.52, p<0.001; Nigeria OR 0.53, 95% CI 0.38 to 0.76, p<0.001).
CONCLUSIONS
Impact of SMC can be detected in reduced prevalence of malaria from data collected through household surveys if conducted during SMC administration or within 2 months afterwards. Such evidence could contribute to broader evaluation of impact of SMC programmes.
Identifiants
pubmed: 35589153
pii: bmjgh-2021-008021
doi: 10.1136/bmjgh-2021-008021
pmc: PMC9121431
pii:
doi:
Substances chimiques
Antimalarials
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Lancet. 2020 Dec 5;396(10265):1829-1840
pubmed: 33278936
PLoS Med. 2011 Feb 01;8(2):e1000408
pubmed: 21304925
Am J Trop Med Hyg. 2018 Feb;98(2):524-533
pubmed: 29260654
BMC Infect Dis. 2014 Feb 26;14:109
pubmed: 24568311
Malar J. 2017 Aug 10;16(1):325
pubmed: 28797263
Trop Med Int Health. 2006 Jul;11(7):983-91
pubmed: 16827699
Antimicrob Agents Chemother. 2015 Aug;59(8):4387-96
pubmed: 25918149
BMC Med. 2007 Dec 11;5:37
pubmed: 18072976
Ann Am Thorac Soc. 2019 Jan;16(1):22-28
pubmed: 30230362
Lancet. 2019 Jul 27;394(10195):322-331
pubmed: 31229234
J Trop Med. 2020 Jul 1;2020:9372457
pubmed: 32665781
Sci Rep. 2018 May 25;8(1):8104
pubmed: 29802375
N Engl J Med. 2021 Sep 9;385(11):1005-1017
pubmed: 34432975
Nat Commun. 2012 Jun 06;3:881
pubmed: 22673908
Malar J. 2012 May 31;11:137
pubmed: 22545931
Nat Commun. 2021 May 11;12(1):2635
pubmed: 33976132
BMC Med Inform Decis Mak. 2020 Dec 17;20(1):340
pubmed: 33334323
Nature. 2015 Dec 3;528(7580):S86-93
pubmed: 26633770
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003756
pubmed: 22336792
Am J Trop Med Hyg. 2017 Sep;97(3_Suppl):46-57
pubmed: 28990915
BMC Med. 2020 Jun 3;18(1):121
pubmed: 32487080
Health Policy Plan. 2016 Feb;31(1):129-35
pubmed: 25887561